Counterpath soars after it is awarded authentication patent

Counterpath CEO Donovan Jones.

Shares of Counterpath (TSX:CCV) gained more than 27% Monday after the company was granted a patent for network based authentication. The Vancouver-based mobile application software company was awarded United States patent No. 8,763,081 from the U.S. Patent and Trademark Office. The patent will come as relief to those tired of trying to remember the host [...]

Should the City of Vancouver really be in the venture capital business?


A proposal currently in front of Vancouver City Council would see it establish a venture capital fund to aid a sector it sees as “diffuse, poorly connected and relatively risk-averse” and suffers from a lack of access to capital. The plan would see the Vancouver Economic Commission budget increased in 2015, 2016 and 2017 to [...]

BuildDirect advisory board to be headed by Art Mesher

Mesher: "BuildDirect is the one of the most exciting companies I have ever seen."

Former Descartes Systems Group CEO Art Mesher will head a new star-studded advisory board for Vancouver-based ecommerce player BuildDirect. The board will be comprised of Mesher, ex-Amazon exec Mike Swartz, e3 Associates founder Dr. Corey Billington, former COO of of Health Shared Services BC Jim Eckler, and ex-Red Prairie CEO Mike Mayoras. Mesher, who has [...]

Cantor Fitzgerald initiates coverage of BSM Technologies with a $3.00 target

BSM Technologies CEO Aly Rahemtulla.

SaaS-based player BSM Technologies (TSX:GPS) is well positioned to gain market share in the fragmented fleet tracking space, says Cantor Fitzgerald Canada analyst Blair Abernethy. In a research report to clients this morning, Abernethy initiated coverage of BSM with a “Buy” rating and $3.00 one-year target. Abernethy says the telematics industry has literally hundreds of [...]

Buy Urthecast on weakness, says Clarus analyst Ofir

Clarus analyst Eyal Ofir believes the long term prospects for Urthecast have actually improved with Wednesday's announcement that the company will build and install two additional sensors on the NASA segment of the ISS.

The selloff that came after Urthecast (TSX:UR) announced its high-res camera on the International Space Station would be delayed is a buying opportunity for investors with a longer time frame, says Clarus analyst Eyal Ofir. On Wednesday, Urthecast announced that the biaxial pointing platform, which controls the pointing of its high-res camera, is experiencing difficulties [...]

Celestica gets price target raise from Paradigm Capital


Improving margins and a healthy macro environment have led Paradigm Capital analyst Gabriel Leung to raise his price target on Celestica (TSX:CLS). In a research update to clients this morning, Leung maintained his “Buy” rating on Celestica, but raised his one-year target on the stock to $13.50, up a dollar from his previous $12.50 target, [...]

BlackBerry lashes out at “out of date” criticism

BlackBerry says recent comments about its competitiveness in enterprise made by MobileIron CEO Bob Tinker are outdated.

BlackBerry’s PR efforts, which have in the past been accused of being aloof, has taken a feisty and personal turn with its new “BlackBerry Fact Check” blog. A post from yesterday entitled “BlackBerry Fact Check Asks Good and MobileIron CEOs: Are You Sure?” continued the company’s battle for the hearts and minds of enterprise clients [...]

Sandvine to FCC: Pay for Priority Won’t Work

Current FCC Chairman Tom Wheeler is a former wireless industry lobbyist.

On Monday, Waterloo’s Sandvine (TSX:SVC) submitted comments to the FCC’s latest Notice of Proposed Rulemaking (NPRM) on the Open Internet. The FCC has been on the hot seat this year because language from its Chairman, Tom Wheeler, sounded less like a guy who was prepared to defend open access to the internet and more like [...]

Revive Therapeutics has huge upside, says Beacon Securities

Between 2013 and 2019, more than $115-billion in annual pharma sales will lose their patent protection, including that of AstraZeneca's popular anti-cholesterol drug Crestor, which lose market exclusivity in 2016. This represents an opportunity for Revive Therapeutics, says Beacon Securities analyst Doug Cooper.

By finding new uses for existing drugs, Revive Therapeutics (TSXV:RVV) is well positioned in a pharmaceutical industry that is facing a “significant patent cliff”, says Beacon Securities analyst Doug Cooper. In a research report to clients Monday, Cooper initiated coverage of Revive Therapeutics with a “Buy” rating and a one-year price target of $2.00, which [...]

Sheldon Inwentash keeps buying Keek


It’s been a rocky start to public life for social media junior Keek (TSXV:KEK), but the company has at least one shareholder who remains undeterred. Pinetree Capital CEO Sheldon Inwentash, personally and through Pinetree, continues to buy shares of the company in the open market. On July 10th, he bought 500,000 shares of Keek at [...]